Denali Therapeutics Inc (DNLI)
US$ 21.43-7.71%
Price Chart
Key Statistics
Market Cap
$ 2.11B
P/E Ratio
0.00
Revenue (TTM)
$ 0
Volume
1.04M
52W High
$ 33.33
52W Low
$ 10.57
Dividend Yield
0.00%
Beta
1.33
Technicals
50-Day MA
14.3536
200-Day MA
19.6974
52 Week High
33.33
52 Week Low
10.57
About DNLI
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases.
Employees
443
Headquarters
South San Francisco, CA
CEO
Dr. Ryan J. Watts Ph.D.
Latest News
$DNLI stock is up 2% today. Here's what we see in our data. - Nasdaq
4 days ago • Google News
When (DNLI) Moves Investors should Listen - news.stocktradersdaily.com
3 days ago • Google News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg